Scarica l'app Stockscreener
4.58
1.29%
-0.06
Exagen Inc Borsa (XGN) Ultime notizie
Enterprise value to revenue forward of Exagen Inc. – NASDAQ:XGN - TradingView
Enterprise value to revenue forward of Exagen Inc. – BOATS:XGN - TradingView
Exagen, Inc. Actuals & Estimates (NASDAQ:XGN) - TradingView
Exagen sets dates for second-quarter results, shares watched around Nasdaq listing - Ad-hoc-news.de
E08A Forecast — Price Target — Prediction for 2027 - TradingView
XGN Forecast — Price Target — Prediction for 2027 - TradingView
XGN Initiates Coverage On Exagen -- Roth Capital Assigns Buy Rat - GuruFocus
Exagen (XGN) Gains Buy Rating with $8 Price Target from Analyst - GuruFocus
Form 4 Exagen Inc For: 24 June By Investing.com - Investing.com Nigeria
Exagen Inc (XGN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Form 4 Exagen Inc For: 22 June By Investing.com - Investing.com Australia
Exagen (XGN) director Scott Kahn receives 37,500 stock options grant - Stock Titan
Exagen (XGN) director granted 37,500 stock options at $4.31 strike - Stock Titan
Exagen (XGN) director Frank Stokes receives 37,500 stock options at $4.31 - Stock Titan
Exagen StockSunday background on autoimmune diagnostics specialist - Ad-hoc-news.de
Exagen advances use of new RA biomarkers to refine patient risk assessment - Traders Union
Exagen Inc (XGN) Institutional Confidence - TradingKey
Exagen (XGN) Stock Draws Fresh Price Target Split After Analysts Trim Targets - Yahoo Finance
Exagen Inc (XGN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Exagen Inc (XGN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Exagen Inc (XGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Exagen Inc (XGN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Exagen Inc (XGN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Exagen Inc (XGN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Exagen Inc (XGN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Exagen Inc. (XGN) Q1 2026 Earnings: Adjusted Loss Narrows, Stock Gains in AftermathSegment Revenue Breakdown - newsline.com
Exagen Shareholders Approve Directors, Auditor and Pay Package - The Globe and Mail
Exagen | 8-K: Current report - Moomoo
Exagen (NASDAQ: XGN) shareholders approve directors, auditor and say-on-pay - Stock Titan
Exagen Company Profile & Introduction - Moomoo
XGN Q1 2026 Earnings: EPS Beats Estimates Despite Stock DeclineRevenue Surprise History - newsline.com
Exagen Inc. Q1 2026 Earnings: EPS Surprise Lifts but Revenue Disclosure Gap Weighs on SharesMargin Compression Risk - newsline.com
Exagen Inc. (XGN) Plunges 9.4% – Key Support Levels in Focus After Sharp SelloffIV Spike - newsline.com
Exagen study shows lupus test identifies 25% more patients By Investing.com - Investing.com South Africa
Exagen study shows lupus test identifies 25% more patients - Investing.com
Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus - GlobeNewswire
Exagen Inc. (XGN) Q1 2026 Earnings: EPS Beats Estimates by 15.15%, Revenue Details Withheld, Stock DeclinesBook Value Growth - The Legal Advocate
Record revenue growth and higher test pricing keep Exagen (XGN) in focus despite ongoing losses - MSN
How much upside is left in Exagen (XGN)? Wall Street analysts think 73.05% - MSN
Exagen Inc. (XGN) reports Q1 loss, beats revenue estimates - MSN
How Much Upside is Left in Exagen (XGN)? Wall Street Analysts Think 73.05% - Yahoo Finance
Parian Ultreia reports 5.3% stake in Exagen (NASDAQ: XGN) - Stock Titan
Exagen Inc. Q1 2026 Earnings: EPS Beat Surprises, but Revenue Details AbsentEstimate Accuracy - The Legal Advocate
XGN Q1 2026 Earnings: EPS Beat Highlights Cost Discipline Amid Revenue UncertaintyEarnings Weakness Phase - Newser
Exagen Inc. (XGN) Holds Steady Near Support Amid Low VolatilityLiquidity Sweep - The Legal Advocate
Exagen Inc. (XGN) Inches Lower as Shares Test Key Support Near $4.05Institutional Volume - The Legal Advocate
William Blair Maintains Exagen(XGN.US) With Buy Rating - Moomoo
1.76%
0.62%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):